LGND:NASDAQ
Ligand Pharmaceuticals Inc
$293.26
0.00%
(0.00) 1 دن
7 اکتوبر, 4:00:00 PM GMT -4 · USD
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoLGND کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
مارکیٹ کی سرمایہ کاری
5.85 ارب
اوسط والیوم
2.42 لاکھ
والیوم
901.00
P/E تناسب
31.19
52 ہفتے میں اعلی
$326.63
52 ہفتے کا کم
$175.89
EPS
$9.40
بی ٹا
1.06
بقایہ شیئرز
1.99 کروڑ
ملازمین کی تعداد
47
مارکیٹ کی سرمایہ کاری
5.85 ارب
اوسط والیوم
2.42 لاکھ
والیوم
901.00
P/E تناسب
31.19
52 ہفتے میں اعلی
$326.63
52 ہفتے کا کم
$175.89
EPS
$9.40
بی ٹا
1.06
بقایہ شیئرز
1.99 کروڑ
ملازمین کی تعداد
47
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
Yahoo Finance
·
10 گھنٹے پہلے
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts
Benzinga
·
1 دن پہلے
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call
AD HOC NEWS
·
1 دن پہلے
Ligand Pharmaceuticals stock fell 3.2 percent as insiders sold shares
پروفائل
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Ligand Pharmaceuticals Inc کے بارے میں
CEO-
ملازمین47
تاریخ قیامستمبر 1987
ہیڈ کواٹرزJupiter, فلوریڈا, ریاستہائے متحدہ
سیکٹر-
ویب سائٹligand.com